Experience real-time quotes, in-depth charts, and analyst ratings

MARKET

ATRA

Atara Biotherape

NASDAQ

10.17

+0.41

+4.20%

After Hours: 10.35 +0.18 +1.77% 16:31 07/26 EDT

OPEN

9.67

PREV CLOSE

9.76

HIGH

10.18

LOW

9.67

VOLUME

30.48K

TURNOVER

52 WEEK HIGH

63.38

52 WEEK LOW

4.965

MARKET CAP

49.88M

P/E (TTM)

-0.1921

Weekly Report: what happened at ATRA last week (0715-0719)?

Weekly Report · 4d ago

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Stock Catapults 34% Though Its Price And Business Still Lag The Industry

Atara Biotherapeutics, Inc. Share price has bounced 34% in the last month. The company's share price is still down 79% over the last year. The stock has a price-to-sales ratio of 1.5x and trails the rest of the industry. Atara's revenue growth has been going backwards and the company's forecast growth is lower than the wider industry.

Simply Wall St · 5d ago

Atara Biotherapeutics Receives Buy Rating Amidst Positive FDA Review and Solid Financial Outlook

TipRanks · 07/18 10:46

Atara lead asset tab-cel undergoes FDA priority review

Atara Biotherapeutics' lead asset tab-cel undergoes FDA priority review for a post-transplant condition. The U.S. Food and Drug Administration has granted priority review to Atara's lead asset. The company plans to launch the product early next year.

Seeking Alpha · 07/17 19:39

Atara Biotherapeutics Is Maintained at Sell by Goldman Sachs

Dow Jones · 07/17 16:08

Atara Biotherapeutics Price Target Cut to $11.00/Share From $12.50 by Goldman Sachs

Dow Jones · 07/17 16:08

Goldman Sachs Maintains Sell on Atara Biotherapeutics, Lowers Price Target to $11

Benzinga · 07/17 15:58

Atara Biotherapeutics Receives FDA Acceptance And Priority Review Of Biologics License Application For Tabelecleucel For Treatment Of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease

Benzinga · 07/17 13:05

About ATRA

Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company. The Company is a developer of T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. Its pipeline products include Ebvallo (Tab-cel), ATA3219. The Company’s T-cell immunotherapy, tab-cel (tabelecleucel), is in Phase III development for patients with EBV-driven post-transplant lymphoproliferative disease (EBV+ PTLD) who have failed rituximab or rituximab plus chemotherapy, as well as other EBV-driven diseases. Its ATA3219 is in Phase 1 development is being developed as a potential product intended to target B-cell malignancies and autoimmune diseases, based on a next generation 1XX co-stimulatory domain and the innate advantages of EBV T cells as the foundation for an allogeneic CAR T platform.

Webull offers Atara Biotherapeutics Inc stock information, including NASDAQ: ATRA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ATRA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ATRA stock methods without spending real money on the virtual paper trading platform.